A multiple dose Naloxone spray dosage form provides a container having two or more unit doses of Naloxone or a salt thereof in a liquid that is delivered by a metered dosage spray pump. In different embodiments, ten or more, 3-500, and 10-500 unit doses are provided in the container. The metered dosage spray pump delivers 50 to about 200 μL of Naloxone solution per spray, preferably, 100 μL per spray. Each unit dose contains about 0.5 mg to 12 mg of Naloxone or a pharmaceutically acceptable salt thereof, preferably, about 2 mg to 4 mg thereof in the delivered spray. A stable pharmaceutically acceptable composition of Naloxone is used in the multiple dose Naloxone spray dosage form. A method of treatment of opioid overdose involves administration of multiple doses using the multiple dose Naloxone spray dosage form.

Face soaking devices (devices) may include a vessel and a vessel neck gasket. The vessel may be configured to hold a liquid to submerge a face of a user or a portion thereof. The vessel neck gasket may be (removably) joined to the vessel. The vessel neck gasket may be configured to comfortably accommodate a portion of the user's neck. The devices may include a breathing apparatus that may be in removable contact with: the vessel, with a head rest subassembly, and/or with the user. The breathing apparatus may be configured to permit the user to breathe while the user's face may be submerged within the liquid. When the vessel may be filled with the liquid to at least a sufficient level, the user may soak the face or the portion thereof, such that the skin being soaked receives a benefit.

A delivery device for and method of modulating a condition relating to social cognition and/or behaviour in a human subject using oxytocin, non-peptide agonists thereof and/or antagonists thereof, comprising: providing a nosepiece to a first nasal cavity of the subject; and providing a supply unit for administering less than 24 IU of oxytocin, non-peptide agonists thereof and/or antagonists thereof through the nosepiece to an upper region posterior of the nasal valve which is innervated by the trigeminal nerve.

The disclosure relates to a method and a device for obtaining a breath sample of a test person, wherein the test person inhales a droplet mist which is preferably colder than the ambient temperature. The material exhaled and/or ejected by the test person is collected as a breath sample in one or more collection vessels.

Methods and devices for delivering one or more substances within at least one body cavity are provided. The device includes at least one nosepiece including at least one capsule having a volume V.sub.sub of the substances; at least one base in communication with the nosepiece, the base including at least one chamber configured to confine pressurized fluid at volume V.sub.PF and pressure P.sub.PF; and at least one hollow puncturing member. The hollow puncturing member includes at least one end in fluid communication with the nosepiece and a second end in fluid communication with the base. The first and second ends are fluidly interconnected by a hollow tube. The fluid inlet port of the capsule is configured in terms of size and shape to interface in a sealable manner with the one end of the at least one puncturing member.

Diffusion and infusion resistant implantable devices and methods for reducing pulsatile pressure are provided. The implantable device includes a balloon implantable within a blood vessel of a patient, e.g., the pulmonary artery. The balloon is injected with a fluid mixture comprising a constituent fluid(s) and a diffusion-resistant gas to provide optimal balloon volume and limit fluid diffusion throughout multiple cardiac cycles. The fluid mixture may be pressurized such that the balloon is transitionable between an expanded state and a collapsed state responsive to pressure fluctuations in the blood vessel.

The present disclosure provides applicators adapted to or configured to deliver a product therefrom. The applicators can be particularly designed for delivery to certain body parts of the human body, such as to the vaginal area. The applicator can comprise a housing formed of a substantially continuous wall extending along a longitudinal housing axis between a base end and an application end, the substantially continuous wall defining: a base segment extending from the base end toward the applicator end; a delivery segment extending from the applicator end toward the base end; and a compression segment interconnecting the base segment and the delivery segment. The housing can define a substantially hollow interior configured for retaining a product for delivery through the delivery segment.

A cartridge for use with a beneficial agent delivery device having a fillable reservoir. The cartridge includes a reconstitution, unit dose package having first and second compartments, and a fitment. The first compartment contains at least a first constituent of the beneficial agent. The second compartment contains at least a second constituent of the beneficial agent. The fitment is disposed on the package for interfacing the package to the fillable reservoir.

A nosepiece for delivering substance to a nasal cavity of a subject, the nosepiece comprising a body part which comprises a base portion which defines a flow passage therethrough, and a projection at a distal end of the base portion which at least in part provides a tip of the nosepiece and confers a rigidity in the sagittal direction, which enables the tip to open fleshy tissue at an upper region of the nasal valve and thereby expand an open area of the nasal valve, and a flexibility in a lateral direction, orthogonal to the sagittal plane, which facilitates insertion of the tip into the nasal valve.

A device for delivering a predetermined volume a substance within a body cavity. The device includes: at least one predefined volume sized and shaped to contain a predetermined volume the substance; a delivery end in fluid communication with a container; and at least one valve mechanically connected to the container and configurable between an active configuration in which the valve enables delivery of a volume of the substance and an inactive configuration, in which the valve prevents delivery.